header image

Page 16«..10..15161718..3040..»

5 Ways to Save on Your Pet’s Healthcare – The Motley Fool

Image source: Getty Images

Part of loving a pet is paying for care when they need it.

Most of us consider our pets to be family, and there are few things worse than not being able to pay for care when those furry (or feathered, or scaly) family members are in need. Here, we lay out some of the ways you can provide for your pet's health care without draining your bank account.

You may find some of these methods a little "out there," but hopefully, one or two will work for you.

This suggestion may sound insultingly simple, but when my husband and I were young, in college, and broke we looked around for places that provided low-cost vaccinations for our dog. Fortunately, a pet store not far from our apartment provided just such a service. We regularly got in line with other pet owners to have a vet look our dog over and give her the vaccinations she was due. We held on to her vaccination record like it was a passport and made sure she stayed up to date. She lived a long, healthy life.

To ensure that's still "a thing," I just did a quick online search. Our local animal shelter provides low-cost spay and neuter services, as well as free rabies vaccines. There's also an organization that provides discounted vaccination packages for pets of all ages. SNAP recipients get an even deeper discount.

Do not be discouraged if you don't find something right away. Expand your search parameter to include the entire county or call your local humane society to ask about programs not listed online.

No one likes going into debt, but if your pet is sick or injured, applying for a line of credit through a company like Scratchpay or CareCredit can help you cover an emergency situation.

Let's say your pet has a serious condition. CoFund My Pet allows you to upload a picture of your pet and explain why they need veterinary care. When people donate, they know that all funds collected through this crowdfunding site can only be spent at veterinary clinics and won't go to another cause.

There's a good chance you have something sitting around your house that you have no more use for. Or, clean out your basement or attic and sell a whole bunch of stuff. Whether you host a virtual garage sale online or an old-school tag sale in your front yard, all those things you no longer need or use are sure to be of use to someone else. And the money can go to vet bills, or into a savings account for future care.

I suspect that the last thing you want to hear right now is, "You ought to have pet insurance," especially if your pet has an immediate need. However, as someone who has had pets with and without insurance, I need you to know how much it can help. Let's say you have a cat you adore. For less than $10 a month you can buy a policy that will help you pay for whatever may go wrong. It won't cover the entire bill but will pay for 70% to 90% of medical care, depending on the policy you choose.

I have two middle-aged dogs and pay less than $52 per month to cover them both ($26 each). You could easily find a less expensive monthly premium, but this policy pays for everything -- from surgery to chemotherapy, all the way to stem cell replacement. If it sounds excessive, it's because I've made a medical decision on behalf of a dog based, in part, on how much treatment was going to cost and I promised myself (and that dog) I would never do it again.

No matter what, if your pet is suffering, don't give up. If you can't find help locally, contact an organization that specializes in this realm. Some examples include:

Veterinary care is expensive. Fortunately, there are a lot of good people in this world willing to help cover the costs.

If you don't currently have a plan in place to pay for pet healthcare, today is the day to decide what you'll do if your pet is sick or injured. Waiting until your pet is in pain will only add to your stress.

More here:
5 Ways to Save on Your Pet's Healthcare - The Motley Fool

Westin and Sehn Carve Out the Role of CAR T-Cell Therapy and Transplant in Primary Refractory DLBCL – OncLive

CAR T-cell therapy, autologous stem cell transplant (ASCT), and novel agents each have a role to play in the second-line management of patients with primary refractory diffuse large B-cell lymphoma (DLBCL), according to Jason Westin, MD, MS, FACP, and Laurie H. Sehn, MD, MPH, who provided perspective on the optimal use of each modality during a case-based presentation at the 2022 Pan Pacific Lymphoma Conference.1,2

Westin, director, Lymphoma Clinical Research, section chief, Aggressive Lymphoma, and associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, started the session by presenting a case of a 70-year-old man with a failure to thrive with progressive bowel obstruction. The man had decreased urine output, a performance status of 1, rising lactate dehydrogenase (LDH) of 1.5 x the upper limit of normal, and an International Prognostic Index (IPI) of 4. A biopsy confirmed high-grade double-hit DLBCL with MYC and BCL2 translocations.

The patient was started with dose-adjusted R-EPOCH and although his gastrointestinal (GI) symptoms improved during the first cycle of chemotherapy, he developed worsening shoulder pain in weeks 2 and 3 of cycle 2 of treatment. An interim PET scan performed after 2 cycles of treatment confirmed a significant improvement in tumor burden but persistent hypermetabolic lesion in the right humerus and a standardized uptake value of 7.

There is a lot of controversy in our field about how we interpret an interim positive PET [result], Westin said. We know the negative predictive value is strong, but the positive predictive value is rather poor.

As such, a bone biopsy was performed on the lesion in the humerus, confirming CD10-positive B-cell lymphoma. Westin argued that the patient was unlikely to achieve a complete response (CR) at the end of treatment, and as such, alternative regimens should then be considered. However, patients with refractory disease have poor outcomes with salvage chemotherapy, which led Westin to consider a clinical trial.

[ZUMA-12 (NCT03761056)] was the clinical trial we had open at the time, which Ill argue is something we should consider for our patients who have high-risk disease in the frontline setting: an early switch to a CAR T-cell therapy, Westin said.

The phase 2 trial enrolled patients with high-grade double-hit or triple-hit B-cell lymphoma and large B-cell lymphoma with an IPI score of at least 3.3 Patients had to have a positive interim PET scan following 2 cycles of an anti-CD20 monoclonal antibody and anthracycline-containing regimen.

Patients underwent leukapheresis and optional nonchemotherapy bridging therapy followed by conditioning chemotherapy consisting of 30 mg/m2 of intravenous (IV) fludarabine and 500 mg/m2 of IV cyclophosphamide on days 5, 4, and 3. They subsequently received a single IV infusion of axicabtagene ciloleucel (axi-cel; Yescarta) at 2 x 106 CAR T cells/kg on day 0.

The CR rate achieved with the CAR T-cell therapy was impressive, according to Westin, at 78% (n = 29) and benefit was consistent across subgroups. The 1-year event-free survival rate with axi-cel was 72.5% (95% CI, 53.1%-84.9%).

In terms of safety, cytokine release syndrome (CRS) occurred in all patients, but the rate of grade 3 CRS was low, at 8%, Westin said.

Westin acknowledged that although axi-cel could be saved for relapse, findings presented at the 2021 ASH Annual Meeting and Exposition comparing the populations in ZUMA-12 and ZUMA-1 (NCT02348216) showed better CAR T-cell expansion in patients who had received less chemotherapy.4

With this in mind, the patient was enrolled to ZUMA-12. He developed late, low-grade CRS and immune effector cellassociated neurotoxicity syndrome (ICANS) but went on to achieve a CR with treatment.

Hes more than 2 years out now without any relapse or any late toxicities, Westin said. Should you switch all patients with a positive interim PET? No. However, if you have circulating tumor DNA or a positive biopsy, its reasonable to consider switching to a different therapy. Having a non-chemotherapy option for chemorefractory disease makes treatment switch more attractive.

Laurie H. Sehn, MD, MPH, a clinical associate professor in the division of medical oncology at the University of British Columbia and the British Columbia Cancer Agency, subsequently presented a case of a 66-year-old man with stage IVB DLBCL with lymphadenopathy above and below the diaphragm. He had a large bowel mass that was biopsied, confirming germinal center B-cell DLBCL and was negative for MYC, BCL2, and BCL6 on fluorescence in situ hybridization.

The patient was treated with 6 cycles of R-CHOP and achieved a CR; however, 6 months later, the patient developed GI bleeding and was found to have recurrent DLBCL of the GI tract. He was started on 2 cycles of R-GDP and achieved a CR, with the intention of heading to ASCT.

Our longstanding management for relapsed/refractory DLBCL has been to take patients down the ASCT route, Sehn stated. However, only approximately half of patients will respond to salvage chemotherapy and proceed to transplant, making the decision on what to pursue a difficult one, Sehn explained.

The 3 randomized trials that have evaluated second-line CAR T-cell therapyZUMA-7 (NCT03391466), TRANSFORM (NCT03575351), and BELINDA (NCT03570892)have yet to show an overall survival (OS) benefit, supporting the rationale to opt for a stepwise approach.

Sehn noted that although all 3 trials demonstrated that CAR T-cell therapy would be the preferred approach in the second-line setting in the intent-to-treat population, they do not provide insight into the preferred approach for patients who respond to salvage chemotherapy.

This is a scenario we all face because most people do receive bridging therapy prior to going on to CAR T-cell therapy, even if your intention is to give it in the second-line setting, Sehn said. As such, we all face this question.

Although not randomized data, Sehn highlighted findings from a Center for International Blood and Marrow Transplant Research retrospective registry analysis which showed that patients in partial remission after salvage chemotherapy had a lower rate of relapse and disease progression (P = .010), as well as improved OS (P = .007).5

Moreover, supplementary findings from the ZUMA-7 trial demonstrated a comparable duration of response among responders, regardless of whether they were randomized to axi-cel or standard of care (HR, 0.763; 95% CI, 0.488-1.108).6

Additionally, Sehn stated that the one-size-fits-all design of the CAR T-cell therapy trials is not likely to hold up in the real world because not everyone will benefit from cellular therapy. Sehn cited data published in Blood Advances showing that predictive factors, including at least 2 extranodal sites, total metabolic tumor volume greater than 80 mL, and elevated LDH, is associated with poor outcomes following CAR T-cell therapy.7

In the CAR T trials, everybody went to CAR T based on an intent-to-treat approach, and even though those arms did better, most patients did relapse or progress subsequently, Sehn said. Just blindly taking everyone on to CAR T is probably not going to be feasible in most clinical settings.

In addition, the short- and long-term toxicities associated with CAR T-cell therapy are worth considering, said Sehn, who highlighted CRS, ICANS, prolonged cytopenias, hypogammaglobulinemia, CD19 loss, and B-cell aplasia in particular, which was present in 34% of patients on the ZUMA-7 trial up to 18 months after infusion.5

For patients who are not candidates to receive CAR T-cell therapy or ASCT, Sehn highlighted the potential of novel agents such as polatuzumab vedotin-piiq (Polivy) plus bendamustine and rituximab (Rituxan) and the combination of tafasitamab-cxix (Monjuvi) and lenalidomide (Revlimid), which have shown responses of 40.2% and 60%, and a median progression-free survival of 5.1 months and 11.6 months, respectively.7,8

For patients with primary refractory or early relapsing DLBCL, the data do argue for CAR T-cell therapy as the preferred potential second-line therapy. However, theres still a role for ASCT; [this approach] still might be suitable for patients who respond to salvage or bridging therapy, Sehn concluded. One of the main things we need to figure out is who shouldnt go to CAR T-cell therapy, as its unlikely to work for patients with fully uncontrollable disease. As far as the novel agents go, there are encouraging data to suggest that these [drugs] will improve outcomes in the refractory setting, although we do need predictive markers to figure out which option to select for which patient.

Read the rest here:
Westin and Sehn Carve Out the Role of CAR T-Cell Therapy and Transplant in Primary Refractory DLBCL - OncLive

Codex Beauty Labs Introduces Shaant: A Collection of Four Microbiome-Supporting Products for Oily and Acne-Prone Skin – Yahoo Finance

SAN JOSE, Calif., July 25, 2022 /PRNewswire/ -- Codex Beauty Labs, Silicon Valley's plant-based biotech skincare company launched its third collection called Shaant, that addresses oily and acne-prone skin by helping to reduce sebum production, exfoliate, encourage skin turnover and soothe irritation. Shaant, meaning "peace" and "calm" in Hindi, is often paired with "connectedness" in Ayurvedic philosophy.

Logo

"Increasing levels of stress in our society, stress, poor quality sleep, rising pollution, as well as unhealthy eating and alcohol habits have all contributed to increased acne in both teenagers and adults. Through Ayurvedic plant databases in India, we have identified actives that address two root causes, namely sebum overproduction, and accumulation of dead skin cells in pores," says Dr. Barb Paldus, Founder and CEO of Codex Beauty Labs. "Shaant also leverages our patented PreservX preservation system that supports microbiome health so we are proud that Shaant is the first MyMicrobiome-certified collection for acne-prone skin."

The Shaant products were formulated in partnership with Dr. Raja Sivamani, an integrative dermatologist and certified Ayurvedic practitioner, and leverage biotech-manufactured plant stem cells from Indian plants long valued by Ayurvedic healers for their calming, soothing and balancing properties.

"I am committed to individualizing patient care and my passion for practical research. By integrating concepts from Ayurvedic medicine, plant sciences, and food sciences, I look to push the boundaries of integrative therapies to make them better for our patients and to better educate those around me. This is the philosophy behind the Shaant skincare collection for acne-prone skin: Ayurvedic plants, such as gotu kola or patchouli, that have been vetted with Western scientific tools, like their effect on gene expression in skin cells and clinical tests on patients with acne." Dr. Sivamani added, "I always love to try to bridge the Ayurvedic principles into the western principles. The way Ayurveda looks at the body is slightly different, but actually it really beautifully integrates with the western approach when you start building these bridges. Shaant is a great example of this confluence."

Story continues

The collection will launch in two phases:

The collection harnesses the patent-pending ShaantComplex, a proprietary blend of derived from terrestrial and marine plants that help control oiliness, shed dead skin cells, reduce pore diameter, and help reduce redness. Each plant addresses the acne inflammasome in distinct yet synergistic ways. The ShaantComplex is supplemented by other Ayurvedic plants or fruits that are known for their analgesic, anti-inflammatory, and skin tone improving properties.

The first four Shaant products are certified MyMicrobiome, Vegan, Leaping Bunny, and EWG Verified. The cleanser and toner are also certified EcoCert COSMOS natural.

Everyproduct in the Shaant collection undergoes efficacy testing at a third-party clinical facility. Measurements are made on a statistically meaningful population using instrumentation accepted by dermatologists for quantifying specific skin parameters. This data is summarized in an efficacy panel that provides a transparent snapshot of product performance to the consumer. The entire collection, including future OTC products, is undergoing an IRB clinical trial under the supervision of Dr. Sivamani.

All products are manufactured in a high-tech cosmetic cGMP (ISO22716) facility to deliver the highest quality. All products contain sustainably sourced ingredients housed inplant-based polyethylene tubes or 50% PCR PET bottles, which reduce each product's carbon footprint from about 50% to 100%.

About Codex Beauty Labs

Based in Silicon Valley and led by scientist Dr. Barb Paldus, Codex Beauty Labs is committed to creating the highest standard in sustainable skincare and biotech plant-based alternatives to restore and protect the skin barrier and support a healthy microbiome. The products address key skincare concerns and conditions including eczema, psoriasis, sensitive, dry, and inflamed skin. The brand has been heralded by dermatologists for creating effective, clinically proven skincare that brings a new data-driven and transparent approach to beauty. Codex Beauty Labs is also dedicated to protecting biodiversity to ensure it flourishes for future generations. All products contain sustainably sourced ingredients from the forests of Patagonia to the bogs of Ireland packaged in plant-based polyethylene tubes, while reducing carbon footprint across all touchpoints. The products are sold around the world in over 15 countries and territories.

Codex Beauty Labs Shaant Collection

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/codex-beauty-labs-introduces-shaant-a-collection-of-four-microbiome-supporting-products-for-oily-and-acne-prone-skin-301591871.html

SOURCE Codex Beauty Labs

View original post here:
Codex Beauty Labs Introduces Shaant: A Collection of Four Microbiome-Supporting Products for Oily and Acne-Prone Skin - Yahoo Finance

Global Animal Health Market To Be Driven By The Increasing Pet Ownership In The Forecast Period Of 2022-2027 This Is Ardee – This Is Ardee

The new report by Expert Market Research titled, Global Animal Health Market Size, Share, Price, Trends, Growth, Report and Forecast 2022-2027, gives an in-depth analysis of the globalanimal health market, assessing the market based on its segments like animal types, product types, end uses, and major regions. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porters Five Forces models.

Get a Free Sample Report with Table of Contents https://bityl.co/Ci3L

The key highlights of the report include:

Market Overview (2017-2027)

Forecast CAGR (2022-2027): 3.8%

The animal health industry is driven by the increasing pet ownership, which is driving the demand for companion animal products. Additionally, the rapid globalisation and exchange of animals or animal products from one country to another is leading to an unprecedented rise in animal diseases, resulting in the increased demand for medications and vaccines. In this regard, the growing government initiatives to improve animal health to prevent epidemics are also expected to contribute to the growth of the industry. Moreover, the large-scale adoption of livestock in the agriculture and animal husbandry sector to meet the expanding nutritional requirements of the increasing global population is expected to drive the market growth.

Industry Definition and Major Segments

Animal health involves the regular check-up of animals to ensure the absence of diseases or illnesses in them by analysing the standard animal behaviour patterns. The upkeep of animal health is critical in order to protect animals from illnesses and mitigate the risk of spread of any infection through them. In addition, animal health has become an essential aspect in todays world with the growing pet ownership across the globe.

Read Full Report with Table of Contents https://bityl.co/Ci3K

The animal health industry, by animal type, can be segmented into:

Commercial Animals

oPoultryoSwineoCattleo Sheep and Goato Others

Companion Animals

o Dogso Catso Others

Based on product type, the market is segmented into:

VaccinesPharmaceuticalsFeed AdditivesDiagnostics Others

On the basis of end use, the market is classified as follows:

Veterinary Hospitals and Clinics Animal Care and Rehabilitation Centres Diagnostics Centres Others

The regional market for animal health include:

North America Europe Asia Pacific Latin America Middle East and Africa

Market Trends

The growing importance of animals as a companion is the primary motivator for increased pet adoption. As a result, the growing expenditure to curb animal diseases is projected to augment the market growth. In addition, the technological advancements, in confluence with the research and development activities for the development of improved medication and diagnostic solutions such as heat sensors to monitor health vitals, and stem cell technology, among others, is also expected to bolster the industry growth. Furthermore, the increase in the number of national programmes for disease eradication and vaccine certification because of the increasing incidences of zoonotic diseases is expected to propel the industry growth in the forecast period.

Key Market Players

The major players in the industry are Elanco Animal Health Incorporated, Merck Animal Health, Zoetis Inc., Biogenesis Bago, Boehringer Ingelheim International GmbH, Ceva Sante Animale, and Heska Corporation, among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us:

Expert Market Research is a leading business intelligence firm, providing custom and syndicated market reports along with consultancy services for our clients. We serve a wide client base ranging from Fortune 1000 companies to small and medium enterprises. Our reports cover over 100 industries across established and emerging markets researched by our skilled analysts who track the latest economic, demographic, trade and market data globally.

At Expert Market Research, we tailor our approach according to our clients needs and preferences, providing them with valuable, actionable and up-to-date insights into the market, thus, helping them realize their optimum growth potential. We offer market intelligence across a range of industry verticals which include Pharmaceuticals, Food and Beverage, Technology, Retail, Chemical and Materials, Energy and Mining, Packaging and Agriculture.

Media Contact

Company Name: Claight Corporation.Contact Person: Mathew Williams, Business ConsultantEmail: sales@expertmarketresearch.comToll Free Number: US +1-415-325-5166 | UK +44-702-402-5790Address: 30 North Gould Street, Sheridan, WY 82801, USACity: SheridanState: WyomingCountry: United StatesWebsite: https://www.expertmarketresearch.com

Read more reports

Global Albumin Market To Be Driven By The Rising Investments In Pharmaceutical Research And Development (R&D) In The Forecast Period Of 2022-2027

Global Aluminum Composite Panels Market To Be Driven By Expansion Of The Building And Construction Industry In The Forecast Period Of 2022-2027

Global Amaranth Market To Be Driven By The Rising Application Of The Product In The Food Industry In The Forecast Period Of 2022-2027

Global Ambulatory Arrhythmia Monitoring Devices Market To Be Driven By The Increasing Focus On The Early Detection Of Cardiac Diseases In The Forecast Period Of 2022-2027

Global Animal Health Market To Be Driven By The Increasing Pet Ownership In The Forecast Period Of 2022-2027

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

Read more from the original source:
Global Animal Health Market To Be Driven By The Increasing Pet Ownership In The Forecast Period Of 2022-2027 This Is Ardee - This Is Ardee

Negligence in treatment of diseases like glioblastoma can be fatal, seminar told – The News International

Glioblastoma (GBM) is a fast-growing type of central nervous system tumour that forms from glial (supportive) tissue of the brain and spinal cord, with cells that look very different from normal ones, said Dr Ata Ul Aleem Bhatti, ex-instructor neurosurgeon, Aga Khan University Medical College, Dar as Salaam, Tanzania, and consultant neurosurgeon at the South City Hospital, Karachi.

Addressing a public awareness seminar on World GBM Day 2022 in collaboration with the Neurospinal & Cancer Care Postgraduate Institute, he said: Like most brain tumors, GBM grow more rapidly than their benign counterparts and affect the brain in many different ways depending on the part of the brain they are located.

Dr Bhatti further explained: Unfortunately, like most cancers in other parts of the body, the exact cause of GBM is unknown. Glioblastoma itself is not the only form of brain cancer, though it is the most common and most aggressive type. Other malignant brain tumours include medulloblastomas, lymphomas and anaplastic astrocytomas, to mention a few.

Various risk factors linked to developing cancer in the brain include over exposure to radiation and some rare inherited conditions. In all of these cases, the exact connection or link remains a mystery, but we do see a pattern of occurrence.

Again, unfortunately, there are no symptoms that will immediately tell someone they are developing a malignant brain tumour, however, there are some common things to look out for, when a person develops a mass or growth in the brain, either benign or malignant. These include a bad headache, but not the type one gets after spending hours in Karachi traffic or a stressful day. This headache is usually worse in the morning and persistent over several weeks. It may be associated with a feeling of wanting to vomit (nausea) or actually vomiting, which tends to make the person feel better.

Unfortunately, according to Dr Bhatti, at the moment there is no cure for brain cancers. While there are many therapies that are being tried and a lot of experimental work going on, we are yet to find a cure.

Malignant brain tumours are usually treated with a combination of surgery, radiotherapy and chemotherapy.

Sometimes, newer options like hormone therapy, immune therapy and others are also used. Which option is offered depends on the type of cancer involved. Surgery remains a main part of any treatment regime for GBM, since it allows for accurate diagnosis and also reduces the amount of tumour the body has to fight against.

In some cases, an attempt is made to remove as much of the tumour as possible to allow the radiotherapy and chemotherapy be more effective.

Dr Adeel Ahmed Memon, consultant clinical & radiation oncologist and assistant professor at the Karachi Institute of Radiotherapy & Nuclear Medicine (KIRAN), gave a radiation oncologist perspective for GBM.

Radiosurgery is a treatment method that uses specialized radiation delivery systems to focus radiation at the site of the tumor, while minimizing the radiation dose to the surrounding brain. Radiosurgery may be used in selective cases for tumor recurrence, often using additional information derived from MRS or PET scans, he said.

Studies have shown that radiation therapy provides most patients with improved outcomes and longer survival rates when given the combination of surgery, radiation and chemotherapy compared with surgery alone. Radiation also may be used as the sole treatment when a glioblastoma tumor is in an area that is not appropriate for surgery.

Guest speaker Dr Reena Kumari, consultant medical oncologist & assistant professor at Dr Ziauddin University Hospital, also shared her views regarding the role of chemotherapy, targeted & immunotherapy and discussed why GBM was difficult to treat brain tumor.

When treating GBM, she explained, what makes treatment challenging is that you have tumor cells that are not active, meaning they are dormant. These cells are known as cancer stem cells and since they are not active they do not die by radiation and chemotherapy.

Unlike other cancers such as breast or lung, brain tumors are extremely genetically heterogeneous means there is a high degree of variation within the same tumor cells that makes each individual glioblastoma molecularly distinct. This can be challenging when predicting prognosis and treatment, if it is in an area which is difficult access, or too close to major blood vessels or other important centers of the brain, it can make surgery tough, tendency of the tumor to come back aggressively is also a great challenge.

A promising targeted treatment is the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab. It has been approved by FDA for several different types of cancer, including. Angiogenesis is a key survival feature of many cancers as tumors rely on nutrients from the vasculature to proliferate

A clinical trial has found that selinexor, the first of a new class of anti-cancer drugs called selective inhibitors of nuclear export (SINE) , is able to shrink tumors in almost a third of patients with recurrent glioblastoma,

Dr Kumari urged people to be careful, saying: Negligence in treatment of diseases like GBM can be fatal. She further said that timely treatment of brain tumor was very important as chances of relapsing increases with the grade of tumor.

Dr Sadia Afsar, in-Charge, Neurosurgery Department, Abbasi Shaheed Hospital , highlighted the problems faced by patients with GBM and other brain tumors as this is ignored by community.

Government needs to realise that these conditions are quite common and provide more facilities for early diagnosis and treatment of GBM & other types of brain tumors like MRI, CT-Scan & PET-CT Scanner must be readily available across the country to enhance diagnosis.

The scarcity of Radiotherapy modalities in the country has already been highlighted by her and said that a huge time is wasted in long queue, additionally. The teaching hospitals need to also be equipped to perform proper neurosurgery department and OT, as this is the first step in any treatment programme for brain tumors, including GMBs.

See the rest here:
Negligence in treatment of diseases like glioblastoma can be fatal, seminar told - The News International

Have Fun And Support Local Artists+Pee-Cycling The Way Of The Futute – Patch

Hello, friends. It's me, Karena Garrity, your host of the Essex-Chester-Deep River Daily back in your inbox with everything that's fit to print about what's happening locally. Let's have at it...

First, today's weather:

A dangerous afternoon t-storm. High: 88 Low: 67.

Attention local businesses & marketers: Attract more customers in Essex-Chester-Deep River by sponsoring this daily newsletter, which gets read by the same people you're trying to reach. Click here to learn more.

Here are the top stories in Essex-Chester-Deep River today:

Today in Essex-Chester-Deep River:

From my notebook:

More from our sponsors thanks for supporting local news!

Events:

Now you're in the loop and ready to start this Monday. See you all tomorrow morning for another update!

Karena Garrity

About me: I am a native of Connecticut, who currently resides in the Tri-Town community of Chester, Deep River and Essex. I have been a community reporter for the better part of the past 20 years. I love my small town community and I am honored to be a part of Patch.com. You can reach me at; karena.garrity@patch.com.

Have a news tip or suggestion for an upcoming Essex-Chester-Deep River Daily? Contact me at karena.garrity@patch.com

See the original post here:
Have Fun And Support Local Artists+Pee-Cycling The Way Of The Futute - Patch

Stem Cell and Regenerative Therapy Market: Rise in Prevalence of Different Chronic Diseases across the World to Drive the Market – BioSpace

Wilmington, Delaware, United States, Transparency Market Research Inc.: Stem cells are bodys raw materials or cells from which all other cells with specialized functions are generated. These cells can be guided to become specific cells that regenerate and repair diseased or damaged tissues in patients suffering from various diseases.

Read Report Overview - https://www.transparencymarketresearch.com/stem-cell-and-regenerative-therapy-market.html

This stem cell therapy is called regenerative medicine or regenerative therapy to treat several diseases. Stem cell and regenerative therapy promotes the repair response of diseased, injured, or dysfunctional tissue using stem cells or derivatives of stem cells.

Stem cell therapies can be used to treat patients with Parkinson's disease, amyotrophic lateral sclerosis, diabetes type 1, Alzheimer's disease, heart disease, stroke, burns, cancer, and osteoarthritis

In advanced therapies, stem cells are used to replace damaged cells and serve as a replacement method for the donor's immune system to fight several types of blood-related diseases and cancer

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75161

Key Drivers and Restraints of Global Stem Cell and Regenerative Therapy Market

Unclear Regulatory Guidelines Hampers Global Market

Get COVID-19 Analysis on Stem Cell and Regenerative Therapy Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=75161

Cell Therapy Segment to Dominate Global Market

Oncology to be Highly Promising Segment

Hospitals to be Major End-user Segment

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=75161

North America to Lead Global Stem Cell and Regenerative Therapy Market

Key Manufacturers Operating in Global Stem Cell and Regenerative Therapy Market

Key manufacturers operating in the global market are:

More Trending Reports by Transparency Market Research

Clinical Laboratory Services Market: https://www.transparencymarketresearch.com/clinical-laboratory-services-market.html

Nasopharyngeal Swabs Market: https://www.transparencymarketresearch.com/nasopharyngeal-swabs-market.html

Blood Purification Equipment Market: https://www.transparencymarketresearch.com/blood-purification-equipment-market.html

Epileptic Seizures Treatment Market: https://www.transparencymarketresearch.com/epileptic-seizures-treatment-market.html

Positron Emission Tomography [PET] Scanners Market: https://www.transparencymarketresearch.com/positron-emission-tomography-pet-scanners-market.html

Ethylene-vinyl Acetate [EVA] Infusion Bags Market: https://www.transparencymarketresearch.com/ethylenevinyl-acetate-eva-infusion-bags-market.html

Bone Graft Substitutes Market: https://www.transparencymarketresearch.com/bone-graft-substitutes-market.html

Corporate Wellness Market: https://www.transparencymarketresearch.com/asia-pacific-corporate-wellness-market.html

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.comBlog: https://tmrblog.comEmail: sales@transparencymarketresearch.com

Read more:
Stem Cell and Regenerative Therapy Market: Rise in Prevalence of Different Chronic Diseases across the World to Drive the Market - BioSpace

The ‘Benjamin Button’ effect: Scientists can reverse aging in mice. The goal is to do the same for humans – KITV Honolulu

In molecular biologist David Sinclair's lab at Harvard Medical School, old mice are growing young again.

Using proteins that can turn an adult cell into a stem cell, Sinclair and his team have reset aging cells in mice to earlier versions of themselves. In his team's first breakthrough, published in late 2020, old mice with poor eyesight and damaged retinas could suddenly see again, with vision that at times rivaled their offspring's.

"It's a permanent reset, as far as we can tell, and we think it may be a universal process that could be applied across the body to reset our age," said Sinclair, who has spent the last 20 years studying ways to reverse the ravages of time.

"If we reverse aging, these diseases should not happen. We have the technology today to be able to go into your hundreds without worrying about getting cancer in your 70s, heart disease in your 80s and Alzheimer's in your 90s." Sinclair told an audience at Life Itself, a health and wellness event presented in partnership with CNN.

"This is the world that is coming. It's literally a question of when and for most of us, it's going to happen in our lifetimes," Sinclair told the audience.

"His research shows you can change aging to make lives younger for longer. Now he wants to change the world and make aging a disease," said Whitney Casey, an investor who is partnering with Sinclair to create a do-it-yourself biological age test.

While modern medicine addresses sickness, it doesn't address the underlying cause, "which for most diseases, is aging itself," Sinclair said. "We know that when we reverse the age of an organ like the brain in a mouse, the diseases of aging then go away. Memory comes back; there is no more dementia.

"I believe that in the future, delaying and reversing aging will be the best way to treat the diseases that plague most of us."

A reset button

In Sinclair's lab, two mice sit side by side. One is the picture of youth, the other gray and feeble. Yet they are brother and sister, born from the same litter -- only one has been genetically altered to age faster.

If that could be done, Sinclair asked his team, could the reverse be accomplished as well? Japanese biomedical researcher Dr. Shinya Yamanaka had already reprogrammed human adult skin cells to behave like embryonic or pluripotent stem cells, capable of developing into any cell in the body. The 2007 discovery won the scientist a Nobel Prize, and his "induced pluripotent stem cells," soon became known as "Yamanaka factors."

However, adult cells fully switched back to stem cells via Yamanaka factors lose their identity. They forget they are blood, heart and skin cells, making them perfect for rebirth as "cell du jour," but lousy at rejuvenation. You don't want Brad Pitt in "The Curious Case of Benjamin Button" to become a baby all at once; you want him to age backward while still remembering who he is.

Labs around the world jumped on the problem. A study published in 2016 by researchers at the Salk Institute for Biological Studies in La Jolla, California, showed signs of aging could be expunged in genetically aged mice, exposed for a short time to four main Yamanaka factors, without erasing the cells' identity.

But there was a downside in all this research: In certain situations, the altered mice developed cancerous tumors.

Looking for a safer alternative, Sinclair lab geneticist Yuancheng Lu chose three of the four factors and genetically added them to a harmless virus. The virus was designed to deliver the rejuvenating Yamanaka factors to damaged retinal ganglion cells at the back of an aged mouse's eye. After injecting the virus into the eye, the pluripotent genes were then switched on by feeding the mouse an antibiotic.

"The antibiotic is just a tool. It could be any chemical really, just a way to be sure the three genes are switched on," Sinclair said. "Normally they are only on in very young developing embryos and then turn off as we age."

Amazingly, damaged neurons in the eyes of mice injected with the three cells rejuvenated, even growing new axons, or projections from the eye into the brain. Since that original study, Sinclair said his lab has reversed aging in the muscles and brains of mice and is now working on rejuvenating a mouse's entire body.

"Somehow the cells know the body can reset itself, and they still know which genes should be on when they were young," Sinclair said. "We think we're tapping into an ancient regeneration system that some animals use -- when you cut the limb off a salamander, it regrows the limb. The tail of a fish will grow back; a finger of a mouse will grow back."

That discovery indicates there is a "backup copy" of youthfulness information stored in the body, he added.

"I call it the information theory of aging," he said. "It's a loss of information that drives aging cells to forget how to function, to forget what type of cell they are. And now we can tap into a reset switch that restores the cell's ability to read the genome correctly again, as if it was young."

While the changes have lasted for months in mice, renewed cells don't freeze in time and never age (like, say, vampires or superheroes), Sinclair said. "It's as permanent as aging is. It's a reset, and then we see the mice age out again, so then we just repeat the process.

"We believe we have found the master control switch, a way to rewind the clock," he added. "The body will then wake up, remember how to behave, remember how to regenerate and will be young again, even if you're already old and have an illness."

Science already knows how to slow human aging

Studies on whether the genetic intervention that revitalized mice will do the same for people are in early stages, Sinclair said. It will be years before human trials are finished, analyzed and, if safe and successful, scaled to the mass needed for a federal stamp of approval.

While we wait for science to determine if we too can reset our genes, there are many other ways to slow the aging process and reset our biological clocks, Sinclair said.

"The top tips are simply: Focus on plants for food, eat less often, get sufficient sleep, lose your breath for 10 minutes three times a week by exercising to maintain your muscle mass, don't sweat the small stuff and have a good social group," Sinclair said.

What controls the epigenome? Human behavior and one's environment play a key role. Let's say you were born with a genetic predisposition for heart disease and diabetes. But because you exercised, ate a plant-focused diet, slept well and managed your stress during most of your life, it's possible those genes would never be activated. That, experts say, is how we can take some of our genetic fate into our own hands.

Cutting back on food -- without inducing malnutrition -- has been a scientifically known way to lengthen life for nearly a century. Studies on worms, crabs, snails, fruit flies and rodents have found restricting calories "delay the onset of age-related disorders" such as cancer, heart disease and diabetes, according to the National Institute on Aging. Some studies have also found extensions in life span: In a 1986 study, mice fed only a third of a typical day's calories lived to 53 months -- a mouse kept as a pet may live to about 24 months.

Studies in people, however, have been less enlightening, partly because many have focused on weight loss instead of longevity. For Sinclair, however, cutting back on meals was a significant factor in resetting his personal clock: Recent tests show he has a biological age of 42 in a body born 53 years ago.

"I've been doing a biological test for 10 years now, and I've been getting steadily younger for the last decade," Sinclair said. "The biggest change in my biological clock occurred when I ate less often -- I only eat one meal a day now. That made the biggest difference to my biochemistry."

Additional ways to turn back the clock

Sinclair incorporates other tools into his life, based on research from his lab and others. In his book "Lifespan: Why We Age and Why We Don't Have To," he writes that little of what he does has undergone the sort of "rigorous long-term clinical testing" needed to have a "complete understanding of the wide range of potential outcomes." In fact, he added, "I have no idea if this is even the right thing for me to be doing."

With that caveat, Sinclair is willing to share his tips: He keeps his starches and sugars to a minimum and gave up desserts at age 40 (although he does admit to stealing a taste on occasion). He eats a good amount of plants, avoids eating other mammals and keeps his body weight at the low end of optimal.

He exercises by taking a lot of steps each day, walks upstairs instead of taking an elevator and visits the gym with his son to lift weights and jog before taking a sauna and a dip in an ice-cold pool. "I've got my 20-year-old body back," he said with a smile.

Speaking of cold, science has long thought lower temperatures increased longevity in many species, but whether it is true or not may come down to one's genome, according to a 2018 study. Regardless, it appears cold can increase brown fat in humans, which is the type of fat bears use to stay warm during hibernation. Brown fat has been shown to improve metabolism and combat obesity.

Sinclair takes vitamins D and K2 and baby aspirin daily, along with supplements that have shown promise in extending longevity in yeast, mice and human cells in test tubes.

One supplement he takes after discovering its benefits is 1 gram of resveratrol, the antioxidant-like substance found in the skin of grapes, blueberries, raspberries, mulberries and peanuts.

He also takes 1 gram of metformin, a staple in the arsenal of drugs used to lower blood sugars in people with diabetes. He added it after studies showed it might reduce inflammation, oxidative damage and cellular senescence, in which cells are damaged but refuse to die, remaining in the body as a type of malfunctioning "zombie cell."

However, some scientists quibble about the use of metformin, pointing to rare cases of lactic acid buildup and a lack of knowledge on how it functions in the body.

Sinclair also takes 1 gram of NMN, or nicotinamide mononucleotide, which in the body turns into NAD+, or nicotinamide adenine dinucleotide. A coenzyme that exists in all living cells, NAD+ plays a central role in the body's biological processes, such as regulating cellular energy, increasing insulin sensitivity and reversing mitochondrial dysfunction.

When the body ages, NAD+ levels significantly decrease, dropping by middle age to about half the levels of youth, contributing to age-related metabolic diseases and neurodegenerative disorders. Numerous studies have shown restoring NAD+ levels safely improves overall health and increases life span in yeast, mice and dogs. Clinical trials testing the molecule in humans have been underway for three years, Sinclair said.

"These supplements, and the lifestyle that I am doing, is designed to turn on our defenses against aging," he said. "Now, if you do that, you don't necessarily turn back the clock. These are just things that slow down epigenetic damage and these other horrible hallmarks of aging.

"But the real advance, in my view, was the ability to just tell the body, 'Forget all that. Just be young again,' by just flipping a switch. Now I'm not saying that we're going to all be 20 years old again," Sinclair said.

"But I'm optimistic that we can duplicate this very fundamental process that exists in everything from a bat to a sheep to a whale to a human. We've done it in a mouse. There's no reason I can think of why it shouldn't work in a person, too."

& 2022 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.

Excerpt from:
The 'Benjamin Button' effect: Scientists can reverse aging in mice. The goal is to do the same for humans - KITV Honolulu

Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial | Scientific Reports -…

Patients

Patients were18years old with reported post-COVID-19 cognitive symptoms that affected their quality of life and persisted for more than three months following an RT-PCR test confirming a symptomatic SARS-CoV-2 infection. Patients were excluded if they had a history of pathological cognitive decline, traumatic brain injury or any other known non-COVID-19 brain pathology. The inclusion and exclusion criteria are listed Supplementary information.

A prospective randomized, double blind, sham-controlled, phase II exploratory study was conducted from December 14, 2020, to December 27, 2021, at Shamir Medical Center (SMC), Israel. After signing an informed consent, patients were randomized to either HBOT or sham-control groups in a 1:1 ratio according to a computerized randomization table, supervised by a blinded researcher. To evaluate participant masking, patients were questioned after the first session on their perception regarding the treatment they received. Evaluation procedure was done at baseline and 13weeks after the last HBOT/control session. All evaluators were blinded to the patients group allocation. The study was approved by SMCs Institutional Review Board (IRB) (No. 332-20-ASF) and all participants signed an informed consent prior to their inclusion. All research was performed according to the relevant guidelines and regulations. This study was registered with ClinicalTrials.gov, number NCT04647656 on 01/12/2020.

Both HBOT and sham protocols were administrated in a multi-place Starmed-2700 chamber (HAUX, Germany). The protocol comprised of 40 daily sessions, five sessions per week within a two-month period. The HBOT protocol included breathing 100% oxygen by mask at 2ATA for 90min with five-minute air breaks every 20min. Compression/decompression rates were 1.0m/min. The sham protocol included breathing 21% oxygen by mask at 1.03 ATA for 90min. To mask the controls, the chamber pressure was raised up to 1.2 ATA during the first five minutes of the session along with circulating air noise followed by decompression (0.4m/min) to 1.03 ATA during the next five minutes.

The primary outcome of the study was the cognitive assessment as evaluated by the Mindstreams computerized cognitive testing battery (NeuroTrax Corporation, Bellaire, TX). This assessment evaluates various cognitive domains including: memory, executive function, attention, information processing speed, and motor skills. Cognitive scores were normalized for age, gender and educational levels. The tests methods are described in the Supplementary information.

The secondary outcomes include the following measures:

Brain imaging MRI scans were performed on a MAGNETOM VIDA 3T scanner, configured with 64-channel receiver head coils (Siemens Healthcare, Erlangen, Germany). The MRI protocol included T2-weighted, 3D fluid attenuated inversion recovery (FLAIR), susceptibility weighted imaging (SWI), pre- and post-contrast high-resolution MPRAGE 3D T1-weighted, dynamic susceptibility conSupplementary informationtrast (DSC) for calculating whole-brain quantitative perfusion maps, and diffusion tensor imaging (DTI) for microstructure changes in grey and white matter determination. A detailed description is found in the . Briefly, preprocessing of DSC and DTI images was performed using the SPM software (version 12, UCL, London, UK) and included motion correction, co-registration with MPRAGE T1 images, spatial normalization, and spatial smoothing with a kernel size of 6mm full width half maximum (FWHM). Whole-brain quantitative perfusion analysis was performed as described in previous studies39,40. MR signal intensity was converted to Gd concentrations, AIF was determined automatically, fitted to the gamma variate function and deconvolved on a voxel-by-voxel basis to calculate brain perfusion maps.

Diffusion brain volumes denoising was performed using Joint Anisotropic LMMSE Filter for Stationary Rician noise removal41 and calculation of DTI-FA (fractional anisotropy) and MD (mean diffusivity) maps were performed using an in-house software written in Matlab R2021b (Mathworks, Natick, MA).

Included self-reported questionnaires were the short form-36 (SF-36) to assess quality of life, the Pittsburgh Sleep Quality Index (PSQI) to assess sleep quality, the Brief Symptom Inventory (BSI-18) to evaluate psychological distress, based on three subscales: depression, anxiety, and somatization, and the Brief Pain Inventory (BPI) to measure pain intensity and impact.

The sense of smell was evaluated by the Sniffin Sticks Test (Burghardt, Wedel, Germany). The kit is standardized for age and gender. Taste was evaluated by a Taste Strip Test (Burghardt, Wedel, Germany), including four tastes: bitter, sour, salt and sweet.

Pulmonary function measurements were performed by a KoKo Sx1000 spirometer (Nspire health, USA). Blood samples were collected for complete blood count, chemistry and inflammatory markers. Participants were monitored for adverse events including barotraumas (either ear or sinuses), and oxygen toxicity (pulmonary and central nervous system). This article discusses cognitive and behavioral aspects of post-COVID-19 condition. Additional secondary outcomes including neuro-physical evaluation, cardiopulmonary exercise test, echocardiography, and functional brain imaging will be presented in future manuscripts.

Continuous data are expressed as meansstandard deviations (SD). Two-tailed independent t-tests with were performed to compare variables between groups when a normality assumption held according to a KolmogorovSmirnov test. Net effect sizes were evaluated using Cohen's d method, defined as the improvement from baseline after sham intervention was subtracted from the improvement after HBOT, divided by the pooled standard deviation of the composite score. Categorical data were expressed in numbers and percentages, compared by chi-square/Fishers exact tests. To evaluate HBOTs effect, a mixed-model repeated-measure ANOVA model was used to compare post-treatment and pre-treatment data. The model included time, group and the group-by-time interaction. A Bonferroni correction was used for the multiple comparisons. A value of p<0.05 was considered significant. Pearsons correlations were performed between perfusion and diffusion changes and the change in questionnaire scores before and after HBOT and sham. Imaging data analysis was performed on the normalized CBF, FA and MD maps, using the voxel-based method to generate statistical parametric maps. A gray matter mask was applied on the CBF and MD maps, and a white matter mask on the FA maps (using a threshold of 0.2). A within-subject repeated measure ANOVA model was used to test the main interaction effect between time and group implemented in SPM software (version 12, UCL, London, UK). A sequential Hochberg correction was used to correct for multiple comparisons (P<0.05)42. Data analysis was performed using Matlab R2021b (Mathworks, Natick, MA) Statistics Toolbox.

The estimated sample size was calculated based on our recent study in healthy adults19. A Mindstreams-NeuroTrax global cognitive score improvement of 5.2 and 0.8 points, with a standard deviation of 6.7 points was found in the HBOT and control groups respectively. Assuming a power of 80%, and 5% two-sided level of significance, a total of 74 participants would be required, 37 participants in each arm. Considering a dropout rate of 15% the total sample size required is 85.

See the rest here:
Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial | Scientific Reports -...

India Pet Grooming Products Market To Be Driven By Increasing Pet Ownership And Rising Awareness About The Usage Of Pet Grooming Products In Forecast…

The new report by Expert Market Research titled, India Pet Grooming Products Market Size, Share, Price, Trends, Growth, Report and Forecast 2021-2026, gives an in-depth analysis of the countryspet grooming products market, assessing the market based on its segments like product type and distribution channels. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porters Five Forces models.

Get a Free Sample Report with Table of Contents https://bityl.co/Casr

The key highlights of the report include:

Market Overview (2016-2026)

Forecast CAGR (2021-2026): 13% (India Pet Care Market)

Pet grooming is one of the most important aspect of properly raising a pet. The market for pet grooming products in India is likely to be propelled by the rising awareness of pethealthand well-being. Proper grooming of pet is essential to prevent them from any kind ofdiseases. In India, the market for shampoos and conditioners is likely to grow at a healthy pace as the hairs of cats and dogs needs routine cleaning and nourishment. Also, the increasing use of e-commerce platforms for shopping of pet grooming products is expected to further aid the market growth in the forecast period of 2021-2026.

Industry Definition and Major Segments

Pet grooming is defined as the maintenance and well-being of pets. In includes all the products which are being used by pet owners to take proper care of their pets health and hygiene. By using grooming products, not just a pets good health is maintained but also its physical appearance is simultaneously enhanced.

Read Full Report with Table of Contents https://bityl.co/Casj

Firstly, the market has been segmented based on the product type as:

Shampoos and Conditioners Combs and Brushes Clippers and Scissors Others

Depending on the distribution channel, the Indias pet care market has also been segmented into:

Hypermarkets and Supermarkets Pet Stores Veterinary Clinics Online Others

Market Trends

The shift towards environment friendly products can also be seen in the pet grooming products market. Petveda is one such market player which provides several pet care and grooming products by combining Ayurvdeda and sciences. In 2021, Urban Essentials launched Pawsh, a grooming product range which is SLS and paraben free with no artificial colours orchemicals. Pawsh products have been manufactured using safe ingredients, such as coconut cleansers and essential oils. The new product launches in the market is likely to provide number of alternatives to the Indian pet owners for choosing an environment-friendly option for grooming their pets.

Key Market Players

The major players in the market are Glenand Group of Companies, Petacom, Petkin Inc., Wahl Clipper Corporation, Terrai Natural Products, Scoobee Pet Products, and others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us:

Expert Market Research is a leading business intelligence firm, providing custom and syndicated market reports along with consultancy services for our clients. We serve a wide client base ranging from Fortune 1000 companies to small and medium enterprises. Our reports cover over 100 industries across established and emerging markets researched by our skilled analysts who track the latest economic, demographic, trade and market data globally.

At Expert Market Research, we tailor our approach according to our clients needs and preferences, providing them with valuable, actionable and up-to-date insights into the market, thus, helping them realize their optimum growth potential. We offer market intelligence across a range of industry verticals which include Pharmaceuticals, Food and Beverage, Technology, Retail, Chemical and Materials, Energy and Mining, Packaging and Agriculture.

Media Contact

Company Name: Claight CorporationContact Person: Mathew Williams, Business ConsultantEmail:sales@expertmarketresearch.comToll Free Number: US +1-415-325-5166 | UK +44-702-402-5790Address: 30 North Gould Street, Sheridan, WY 82801, USAWebsite:https://www.expertmarketresearch.com

Read More Reports:

Stem Cell Banking Market:https://www.digitaljournal.com/pr/global-stem-cell-banking-market-to-be-driven-at-a-cagr-of-13-5-in-the-forecast-period-of-2021-2026

Virtual Reality Market:https://www.digitaljournal.com/pr/global-virtual-reality-market-to-be-driven-by-rising-demand-for-virtual-platforms-in-the-forecast-period-of-2021-2026-3

Smart Ticketing Market:https://www.digitaljournal.com/pr/global-smart-ticketing-market-to-be-driven-by-the-rapid-technological-advancements-in-the-forecast-period-of-2021-2026

Automotive Vacuum Pump Market:https://www.digitaljournal.com/pr/global-automotive-vacuum-pump-market-to-be-driven-by-demand-from-the-automotive-pump-market-in-the-forecast-period-of-2021-2026

Engine Driven Welders Market:https://www.digitaljournal.com/pr/global-engine-driven-welders-market-to-be-driven-by-increasing-automation-of-industries-in-the-forecast-period-of-2021-2026

Also, CheckProcurement Intelligencewhich provides you Infallible research solutions.

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

See the original post:
India Pet Grooming Products Market To Be Driven By Increasing Pet Ownership And Rising Awareness About The Usage Of Pet Grooming Products In Forecast...

Back to Top